Clinical Cancer Research · 2014 · 20 citations · 43 references
The finding that downstream inhibitors of RAS signaling and IGF1R inhibitors have synergistic activity warrants further clinical investigation of IGF1R and RAS signaling inhibition as a potential treatment strategy for RAS-driven malignancies.
43
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
Kathryn O’Reilly, F. Rojo, Qing‐Bai She et al. · Cancer Research · 2006 · 2.5K citations · Full text
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 1.5K citations · Full text
BRAF mutation predicts sensitivity to MEK inhibition
David B. Solit, Levi A. Garraway, Christine A. Pratilas et al. · Nature · 2005 · 1.3K citations · Full text